Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01797432 · ClinicalTrials.gov registry record · Phase 2
Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01797432 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 14 participants.
The verdict
NCT01797432, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The investigators hypothesize that Restylane® could serve as a repair matrix which also maintains IL triamcinolone acetonide concentrations at higher levels for a longer period of time in the skin, giving a more sustained local anti-inflammatory effect and thus, arresting the AA process and promoting hair regrowth. Furthermore, the combination of Restylane® with IL triamcinolone acetonide injections may prevent a common side effect, atrophy. With the prevention of scalp atrophy and the preservation of higher concentrations of triamcinolone acetonide for longer periods of time, patients may see a better clinical response for a longer period of time. Quality of life may improve as the number of clinic visits decreases as would the number of IL corticosteroid injections.
Interventions
- DEVICE Restylane
- DRUG Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-03 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01797432
The ClinicalTrials.gov registry entry for NCT01797432 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Restylane is the first listed.
NCT01797432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01797432 about?
NCT01797432 is a clinical study titled "Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata". The investigators hypothesize that Restylane® could serve as a repair matrix which also maintains IL triamcinolone acetonide concentrations at higher levels for a longer period of time in the skin, giving a more sustained local anti-inflammatory effect and thus, arresting the AA process and promotin...
What is the current status of trial NCT01797432?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2009-03. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01797432?
The interventions under investigation include: Restylane (DEVICE), Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) (DRUG).
Who is sponsoring clinical trial NCT01797432?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.